Ovarian Cancer Detection Test

About GENinCode

GENinCode is a commercial-stage diagnostics company focused on genomic risk assessment for cardiovascular disease (CVD). Founded in 2014 and based in Oxford, UK, the company leverages a proprietary platform integrating polygenic risk scores (PRS), monogenic analysis, and clinical algorithms to provide physicians with tools for early intervention. It has secured key partnerships, including with the NHS and Thermo Fisher Scientific, and has obtained regulatory approvals such as New York State clinical test approval for its lead product. The company is positioning itself at the intersection of preventive cardiology and personalized medicine.

Therapeutic Areas